Barclays Increases ConvaTec Group (LON:CTEC) Price Target to GBX 300

ConvaTec Group (LON:CTEC – Get Rating) had its target price hoisted by investment analysts at Barclays from GBX 295 ($3.70) to GBX 300 ($3.76) in a note issued to investors on Friday, MarketBeat reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price target suggests a potential upside of 32.63% from the company’s current price.

Several other research firms also recently commented on CTEC. JPMorgan Chase & Co. restated an “overweight” rating on shares of ConvaTec Group in a report on Tuesday, March 7th. Royal Bank of Canada restated a “sector perform” rating and set a GBX 215 ($2.69) price objective on shares of ConvaTec Group in a research note on Thursday, March 23rd.

ConvaTec Group Trading Up 0.1 %

LON CTEC opened at GBX 226.20 ($2.83) on Friday. The company has a market cap of £4.61 billion, a price-to-earnings ratio of 11,310.00, a P/E/G ratio of 3.11 and a beta of 0.65. ConvaTec Group has a 52 week low of GBX 195.90 ($2.45) and a 52 week high of GBX 257.87 ($3.23). The business has a 50 day moving average price of GBX 221.01 and a 200-day moving average price of GBX 227.91. The company has a quick ratio of 0.96, a current ratio of 1.67 and a debt-to-equity ratio of 80.79.

Insiders Place Their Bets

In other news, insider Karim Bitar sold 429,441 shares of ConvaTec Group stock in a transaction on Tuesday, May 2nd. The stock was sold at an average price of GBX 216 ($2.71), for a total transaction of £927,592.56 ($1,161,959.86). Insiders own 20.31% of the company’s stock.

About ConvaTec Group

(Get Rating)

ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes.